Pritesh Shah, Chief Commercial Officer at NovoCure Ltd (NVCR), sold 15,550 shares at $70.10 ($1.1M) on 2022-03-08, disclosed to the SEC on 2022-03-09.
Seasonal sale ($1.1M) by Chief Commercial Officer — this insider has traded NVCR in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $69.55 | 5,294 | $368K | 34.0% |
| 2 | $69.55 | 5,294 | $368K | 34.0% |
| 3 | $70.10 | 2,481 | $174K | 16.0% |
| 4 | $70.10 | 2,481 | $174K | 16.0% |
| Total | $69.73 avg | 15,550 | $1.1M | 100% |
| Filing → |
| NVCR | SELL | 2023-03-07 | $3.3M | — | Filing → |
| NVCR | SELL | 2023-03-06 | $141K | — | Filing → |
| NVCR | SELL | 2023-03-02 | $294K | — | Filing → |